MAPT and Alzheimer disease: The majority of AD drugs that are currently in the pipeline are disease-modifying agents that intend to prevent or slow disease progression and usually target underlying pathophysiologic mechanisms (e.g., amyloid and/or tau) early in the disease course (3).